Shiau, Carina
Cao, Jingyi
Gong, Dennis
Gregory, Mark T.
Caldwell, Nicholas J. http://orcid.org/0000-0001-8622-0714
Yin, Xunqin
Cho, Jae-Won
Wang, Peter L.
Su, Jennifer http://orcid.org/0000-0003-1798-6542
Wang, Steven
Reeves, Jason W.
Kim, Tae Kyung
Kim, Youngmi
Guo, Jimmy A.
Lester, Nicole A.
Bae, Jung Woo http://orcid.org/0000-0001-5745-4896
Zhao, Ryan http://orcid.org/0009-0009-0204-9370
Schurman, Nathan
Barth, Jamie L.
Ganci, Maria L.
Weissleder, Ralph http://orcid.org/0000-0003-0828-4143
Jacks, Tyler http://orcid.org/0000-0001-5785-8911
Qadan, Motaz
Hong, Theodore S.
Wo, Jennifer Y.
Roberts, Hannah
Beechem, Joseph M. http://orcid.org/0000-0001-8372-5899
Castillo, Carlos Fernandez-del
Mino-Kenudson, Mari http://orcid.org/0000-0002-9092-2265
Ting, David T. http://orcid.org/0000-0002-3261-2322
Hemberg, Martin http://orcid.org/0000-0001-8895-5239
Hwang, William L. http://orcid.org/0000-0003-4514-8837
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (K08CA270417)
Burroughs Wellcome Fund (Career Award for Medical Scientists)
Article History
Received: 22 June 2023
Accepted: 30 July 2024
First Online: 3 September 2024
Competing interests
: W.L.H. and C.S. have received conference travel reimbursements from NanoString Technologies related to presentation of some work in this study. M.T.G., J.W.R., T.K.K., Y.K., N.S. and J.M.B. were employees of NanoString Technologies at the time of their contributions to this study. D.T.T. has received an honorarium from NanoString Technologies, which had technology used in this manuscript. D.T.T. has received consulting fees from ROME Therapeutics and Tekla Capital not related to this work. D.T.T. has received honoraria from Moderna, Ikena Oncology, Foundation Medicine, Inc. and Pfizer that are not related to this work. D.T.T. is a founder and has equity in ROME Therapeutics, PanTher Therapeutics and TellBio, Inc., which is not related to this work. D.T.T. receives research support from ACD-Biotechne, PureTech Health LLC, Ribon Therapeutics, AVA LifeScience GmbH and Incyte, which was not used in this work. W.L.H., J.A.G. and T.J. (U.S. Provisional Application No. 63/069,035) and W.L.H., J.A.G., C.S., J.S. and T.J. (U.S. Provisional Application No. 63/346,670) are coinventors on provisional patents related to the pancreatic cancer states used in this study. The interests of W.L.H. and D.T.T. were reviewed and are managed by Mass General Brigham in accordance with their conflict of interest policies. T.J. is a member of the Board of Directors of Amgen and Thermo Fisher Scientific, and a co-Founder of Dragonfly Therapeutics and T2 Biosystems. T.J. serves on the Scientific Advisory Board of Dragonfly Therapeutics, SQZ Biotech and Skyhawk Therapeutics. T.J. is also President of Break Through Cancer. His laboratory currently receives funding from Johnson & Johnson, but these funds did not support the research described in this manuscript. All other authors declare no interests related to this work.